GlassScriptPhysician profile
Binh Truong
NPI 1134116593
$3,159.45
in general payments reported to CMS, 2019-2025
28 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $155 · 2021: $551 · 2022: $794 · 2023: $512 · 2024: $489 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.76 | 2021-2025 | Vraylar, Synthroid |
| Pfizer INC. | $425.67 | 2019-2024 | |
| Glaxosmithkline, LLC. | $335.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $293.82 | 2019-2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $188.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $172.57 | 2020-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $147.13 | 2021-2025 | Ozempic, Rybelsus |
| Cvrx, INC. | $144.73 | 2023 | Barostim Neo System |
| Edwards Lifesciences Corporation | $122.97 | 2022 | |
| Janssen Biotech, INC. | $120.28 | 2022 | |
| Amarin Pharma, INC. | $103.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $100.54 | 2020-2025 | Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $77.43 | 2022-2024 | |
| Esperion Therapeutics, INC. | $65.76 | 2021-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $61.16 | 2023-2024 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $58.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $46.95 | 2019-2022 | |
| Convatec INC. | $43.36 | 2025 | |
| Sunovion Pharmaceuticals INC. | $35.03 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.79 | 2022 | |
| Astellas Pharma US INC | $23.21 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.87 | 2021 | |
| Radius Health, INC. | $16.50 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.62 | 2022 | |
| Daiichi Sankyo INC. | $15.12 | 2020 | |
| Allergan, INC. | $12.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binh Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.